Skip to content
  1. Home/
  2. Latest news/
  3. What you need to know about Johnson & Johnson’s 2022 fourth-quarter and full-year earnings report
A colorful graphic with people standing in front of charts and graphs

What you need to know about Johnson & Johnson’s 2022 fourth-quarter and full-year earnings report

Check out this infographic breakdown of the company’s fourth-quarter and annual performance, with highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

Fourth-quarter and full-year earnings banner

Today, Johnson & Johnson shared its 2022 fourth-quarter and full-year earnings report.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Johnson & Johnson delivered solid results and demonstrated competitive growth across our business segments in 2022, while managing ongoing macroeconomic challenges,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “We are particularly proud of the pipeline and portfolio advancements in our Pharmaceutical and MedTech businesses as well as the continued progress toward the planned separation of our Consumer Health business, all of which will fortify the foundation for long-term value creation.”

For more details about the company’s 2022 fourth-quarter and full-year results, and to read a message from Chairman of the Board and Chief Executive Officer Joaquin Duato, here’s an infographic highlighting key stats.


An infographic with information on Johnson & Johnson's 2022 Fourth-Quarter and Full-Year Earnings Report

Johnson & Johnson’s 2022 Earnings

Read the earnings press release, which includes fourth-quarter and full-year financial data for 2022.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Using your own cells to fight cancer

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.